
|Articles|November 1, 2004
Intravesical agent shows some promise in treating IC
Whistler, British Columbia, Canada-Intravesical hyaluronic acid (Cystistat) appears to be a simple, quick therapy for reducing pain, frequency, and nocturia in patients with interstitial cystitis, according to Austrian and Canadian researchers. The agent may also improve radiation-induced cystitis and reduce bacterial cystitis recurrences in patients with recurrent urinary tract infections, said Marc Riviere, MD, senior vice president at Belleville, Ontario-based Bioniche Life Sciences Inc., who presented a series of pilot studies at the Canadian Urological Association annual meeting.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
4
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
5











